VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RCEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RCELAvita Medical Inc.
$15.22$378M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
RCEL logo

Avita Medical Inc.

RCEL
NASDAQ · Medical Devices
$15.22
At close - Nov 16, 4:00 PM EST - USD
Market Cap$378M
P/E-13.0x
52W High$18.43
Volume786.02K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Narrowing Losses Clash With Negative Equity And Liquidity Risk

Avita Medical shows an emerging operational inflection, with revenue rising 17.8% year over year to a record $21.7M in 2026Q2 and the operating loss narrowing to $6.9M — its smallest across ten quarters — helped by SG&A falling to $19.5M from $24.7M in 2024Q3.

GrowthMixed
ProfitabilityStrained
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

RCEL price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-151% Peers

P/E is 151% below peer median

03

Market leadership

RS 99 · Leader

High momentum (Outperforming 99% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
RCEL+338.62%
S&P 500 (^GSPC)+8.31%
1-Year Return
RCEL+294.30%
S&P 500 (^GSPC)+11.16%
3-Year Return
RCEL+20.99%
S&P 500 (^GSPC)+59.48%
5-Year Return
RCEL-6.68%
S&P 500 (^GSPC)+53.24%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$72M+11.5% YoY
Net income FY25
-$49M+21.4% YoY
Free cash flow FY25
-$33M+43.5% YoY
Operating margin FY25
-59.4%+28.7 pts YoY
ROIC (FY25)-114.8%
Avg ROIC 5Y-68.7%
ROE (FY25)-
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (25%)
Revenue Beat Rate3/12 (25%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.20+16.5%
vs -$0.24
$26M+16.8%
vs $22M
Q3 2026
Aug 6, 2026
-$0.25+14.6%
vs -$0.29
$21M+6.1%
vs $20M
Q2 2026
May 14, 2026
-$0.35+0.0%
vs -$0.35
$19M+5.2%
vs $18M
Q1 2026
Feb 12, 2026
-$0.38-4.3%
vs -$0.36
$17M-2.3%
vs $18M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
MarketBeat·Nov 6, 2026
Avita Medical Q3 Earnings Call Highlights

Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.

GlobeNewsWire·Nov 5, 2026
AVITA Medical Reports Third Quarter Results

Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth  Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2026.

GlobeNewsWire·Nov 5, 2026
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027

CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule.

GlobeNewsWire·Oct 20, 2026
AVITA Medical to Announce Third Quarter 2026 Financial Results

VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026.

Filtered for Avita Medical Inc.More Headlines
04

Compare before deciding

Benchmark RCEL against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Avita Medical Inc. (RCEL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RCEL logoRCELAvita Medical Inc.Current
$15.22$378.11M-13.0111.45%-42.65%——
XTNT logoXTNTXtant Medical Holdings, Inc.
$0.22$30.86M7.3314.21%-15.92%-36.21%—
TELA logoTELATELA Bio, Inc.
$0.76$34.07M-1.0515.84%-53.57%——
MDXG logoMDXGMiMedx Group, Inc.
$3.18$463.52M-24.1619.99%-6.32%-8.29%—
NVCR logoNVCRNovocure Ltd
$11.30$1.31B-10.848.28%-16.78%-35.81%—
APYX logoAPYXApyx Medical Corporation
$2.65$111.59M-14.029.86%-14.16%-68.79%—

Compare RCEL vs Peers

Avita Medical Inc. (RCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs XTNT

Most directly comparable listed peer for RCEL.

Scale Benchmark

vs SYK

Larger-name benchmark to compare RCEL against a more recognizable public peer.

Peer Set

Compare Top 5

vs XTNT, TELA, MDXG, NVCR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

RCEL SEC Filings & Documents

Avita Medical Inc. (RCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Nov 2, 2026·SEC

Material company update

Aug 11, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 12, 2026·SEC

FY 2025

Feb 13, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 14, 2026·SEC

Get notified when RCEL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RCEL Frequently Asked Questions

Avita Medical Inc. (RCEL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Avita Medical Inc.'s revenue?

Avita Medical Inc. (RCEL) reported $84.7M in revenue over the trailing twelve months. Revenue was $71.6M in fiscal year 2025.

How fast is Avita Medical Inc. growing?

Avita Medical Inc. (RCEL) grew revenue by 17.0% over the trailing twelve months, compared with the twelve months before.

Is RCEL profitable?

No. Avita Medical Inc. (RCEL) reported a net loss of $36.1M over the trailing twelve months.

Dividend & Returns
What is Avita Medical Inc.'s free cash flow?

Avita Medical Inc. (RCEL) had negative free cash flow of $18.2M over the trailing twelve months.

What if you invested $1,000 in RCEL back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →